24/7 Market News Snapshot 16 September, 2025 – Lantern Pharma Inc. Common Stock (NASDAQ:LTRN)

September 16, 2025

DENVER, Colo., 16 September, 2025 (www.247marketnews.com) – (NASDAQ:LTRN) are discussed in this article.
Lantern Pharma Inc. (LTRN) is witnessing a remarkable surge in its stock price, opening at $4.03 and trading up to $4.26, marking an increase of approximately 11.92% following a previous close of $3.81. The rising trading volume of 613.52K shares underscores strong investor interest, suggesting a potential continuation of this bullish trend. Analysts are focusing on key resistance at $4.30 and support at the opening price, making LTRN a stock of significant attention.

In tandem with its stock performance, Lantern Pharma recently announced the successful completion of its Phase 1a clinical trial for LP-184, a revolutionary treatment targeting advanced solid tumors, including glioblastoma multiforme (GBM). The trial, which enrolled 63 patients with relapsed or refractory solid tumors, demonstrated that LP-184 maintains a commendable safety profile, characterized by a low incidence of dose-limiting toxicities. Most adverse events reported were mild (Grade 1 or 2), supporting the therapeutic feasibility of the drug.

Preliminary results are promising, with disease control achieved in 48% of evaluable patients after just two cycles of treatment. Notably, significant responses were observed in patients with genetic mutations related to DNA damage response, as well as those with recurrent GBM who had previously undergone standard care therapies.

Panna Sharma, CEO of Lantern Pharma, emphasized the importance of these developments, acknowledging the collaborative efforts that have laid the groundwork for advancing LP-184. The company is poised to leverage its RADR® AI platform to propel LP-184 into targeted Phase 1b and Phase 2 studies, particularly focusing on triple-negative breast cancer (TNBC), non-small cell lung cancer (NSCLC), and cancers characterized by DNA repair deficiencies. Lantern Pharma plans to release comprehensive clinical trial results for peer-reviewed publication and at upcoming oncology conferences, reaffirming its commitment to advancing cancer treatment innovations.

Related news for (LTRN)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.